Extremity surgeons see a significant amount of nerve damage with a range of causes, including trauma and compression. Each patient presents a unique scenario depending on the mechanism of injury, timing of surgery and nerve injured. You need a nerve repair partner with technologies for all of your nerve needs. Join Axogen at IFSSH in booth 205 to see how these technologies can benefit your practice and patients.
axogen
Biotechnology Research
Alachua, Fl 18,397 followers
revolutionizing the science of nerve repair™
About us
Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.
- Website
-
https://www.axogeninc.com
External link for axogen
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Alachua, Fl
- Type
- Public Company
- Founded
- 2002
- Specialties
- Medical Device, Peripheral Nerve Repair, Biotechnology, Tissue Engineering, Regenerative Medicine, Translational Science, Processed Nerve Allograft, Biologics, Life Science, and Breast Reconstruction Nerve Repair
Locations
Employees at axogen
Updates
-
Axogen is excited to see our fellows this weekend in Phoenix for the FULL Best Practices in Upper Extremities course. If you are interested in attending a future event, visit https://hubs.la/Q039XGtp0
-
-
Watch the full recording of Axogen's Analyst & Investor Day! CEO Michael Dale and our leadership team showcased our innovative nerve repair algorithm, strategic growth initiatives, and financial outlook. See how we’re working to make nerve care the expected standard & drive impact for patients and investors alike. Watch the full replay here: https://lnkd.in/e-2QVYAF
-
-
Axogen is excited to attend the ACFAS Scientific Conference in Phoenix. We look forward to sharing the latest in nerve protection and reconstruction technologies with the country's leading podiatrists in the pursuit of advancing the art and science of foot, ankle, and lower extremity surgery. See you there!
-
-
Today we shared our Q4 and full-year 2024 earnings results, marking a strong year of growth! - Q4 revenue: $49.4M (+15.1% YoY) - Full-year revenue: $187.3M (+17.8% YoY) - Positive cash flow in 2024, a major milestone in our financial performance Join us on March 4th in Tampa, FL, for our Analyst & Investor Day! Our leadership team will discuss our growth strategy, innovation, and vision for the future. Can't attend in person? No problem—a live webcast and 90-day replay will be available. We’re excited for what’s ahead, as we remain focused on advancing our mission to make peripheral nerve care the standard of care for all patients. https://lnkd.in/eGVrSMpG https://lnkd.in/ezmb2_pv
-
Join us in Phoenix March 8 – 9 for a day-and-a-half education program focused on advanced surgical techniques to help optimize peripheral nerve repair outcomes in hand and upper extremity surgery. Click the link to register, https://hubs.la/Q032sz3Z0
-
-
We’re thrilled to share our preliminary fourth-quarter results, highlighting continued growth and enhanced execution of our commercial strategies in 2024. "We are pleased with our fourth-quarter and full-year 2024 performance, which reflects continued improvements in effectiveness and efficiency across the business," said Michael Dale, President and CEO of Axogen. As we move forward, we will remain focused on advancing our mission to make peripheral nerve care the standard of care for all patients. Stay tuned as we continue to drive meaningful progress in this critical area of healthcare. #Axogen #MedTech #Q42024Results #MedicalDevice #BioTech #nerverepair https://lnkd.in/e3vVgk9k
-
Join Axogen next week for an Industry Forum to explore the latest research on the zone of injury after common traumatic injuries, determining when to prioritize nerve protection in non-transected nerve injuries, and strategies for reducing tendon and nerve adhesions to optimize patient recovery. Visit this link to learn more about this event; https://hubs.la/Q031WY480 These links will navigate you away from Axogen’s website. Links outside Axogen’s website are provided as a resource to the viewer. Axogen accepts no responsibility for or control over the content of the linked sites.
-